2026-07-25T23:36:15Zhttps://docta.ucm.es/rest/oai/request
oai:docta.ucm.es:20.500.14352/720662024-09-24T15:29:02Zcom_20.500.14352_14col_20.500.14352_15
Docta Complutense author Díaz Navarro, Marta author Hafian, Rama author Manzano, Irene author Pérez Granda, María Jesús author Cercenado Mansilla, Emilia author Pascual, Cristina author Rodríguez, Carmen author Muñoz, Patricia author Guembe Ramírez, María 2023-06-22T11:03:59Z 2023-06-22T11:03:59Z 2022-01-16 Díaz-Navarro M, Hafian R, Manzano I, Pérez-Granda MJ, Cercenado E, Pascual C, et al. A Dalbavancin Lock Solution Can Reduce Enterococcal Biofilms After Freezing. Infect Dis Ther 2022;11:743–55. https://doi.org/10.1007/s40121-021-00579-4. 2193-8229 10.1007/s40121-021-00579-4 https://hdl.handle.net/20.500.14352/72066 2193-6382 https://doi.org/10.1007/s40121-021-00579-4 https://link.springer.com/article/10.1007/s40121-021-00579-4 Introduction: We previously demonstrated the efficacy of a frozen dalbavancin–heparin (DH) lock solution against biofilms of staphylococci. However, as enterococci also commonly cause catheter-related bloodstream infections (CRBSI), we assessed the bioactivity of frozen dalbavancin (D) and DH against enterococci. Methods: Over 6 months, we compared the bioactivity of a solution of DH (1 mg/ml) with that of D in terms of cfu counts and metabolic activity against biofilms of Enterococcus faecalis and Enterococcus faecium (four strains each). For each solution, we individually compared results obtained at each time point (months 3 and 6) with baseline (month 0). We also compared the median DH value of each variable at baseline and at months 3 and 6 of freezing with the values obtained for D alone. We used both statistical and clinical criteria when results were within 25% of the reference value. Results: At the end of the experiment (month 6), neither a statistically nor a clinically significant reduction in the bioactivity of D solution was observed in terms of cfu count and metabolic activity against enterococcal biofilms. Regarding the DH solution, we found both statistical and clinical significance in the median percentage reduction in metabolic activity between months 0 and 6 in E. faecalis strains (51.8% vs. 77.8%, P = 0.007). Moreover, after freezing, the DH solution lost significant bioactivity compared with the D solution, especially in E. faecalis. Conclusion: A dalbavancin lock solution can be frozen for up to 6 months with no negative effect on its bioactivity against enterococcal biofilms. However, when combined with heparin, its efficacy was reduced. Therefore, we recommend that if lock therapy with frozen dalbavancin is used in the management of enterococcal C-RBSI, heparin should be added simultaneously at the time of catheter lock. eng Atribución-NoComercial 3.0 España A dalbavancin lock solution can reduce enterococcal biofilms after freezing journal article URL https://docta.ucm.es/bitstreams/5f8e6f08-8938-4ce6-89e4-4017716d2d2c/download File MD5 ff4d5e5f904f88ca53c58746b395cfd2 712446 application/pdf Díaz Navarro, Marta et al. 2022. A Dalbavancin Lock Solution Can Reduce....pdf